<DOC>
	<DOCNO>NCT02696525</DOCNO>
	<brief_summary>Conduct prospective study confirm blood urine ctDNA detection value non-small-cell lung cancer patient .</brief_summary>
	<brief_title>Circulating Tumor DNA Detection Surveillance Surgical Lung Cancer Patients</brief_title>
	<detailed_description>Studies show feasibility detect mutation status blood urine circulate tumor DNA ( ctDNA ) non-small cell lung cancer ( NSCLC ) patient . However , prospective conduct usage ctDNA postoperative surveillance NSCLC patient . We plan compare tumor maker radiographic approach blood urine ctDNA surveillance assess lead time postoperative tumor relapse stage ⅢA NSCLC patient . And evaluate correlation ctDNA level tumor relapse metastasis .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Aged 18 80 year Undergo radical surgery（R0 resection） Histologically confirm diagnosis stage ⅢA nonsmall cell lung cancer Positive Driver mutation ( EGFR、PTEN、PIK3CA、BRAF、KRAS、Her2 ) tumor tissue Blood urine circulate tumor detect driver mutation detect tumor tissue Patients must give write informed consent Unable comply study procedure Malignant tumor history within past 5 year Patients receive treatment prior resection R1 R2 resection Coexisting small cell lung cancer Received target drug therapy surgery Unqualified blood urine sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Circulating Tumor DNA</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>lead time</keyword>
</DOC>